© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
Tandem Diabetes Care, Inc. (TNDM) stock surged +4.23%, trading at $15.02 on NASDAQ, up from the previous close of $14.41. The stock opened at $14.42, fluctuating between $14.41 and $15.26 in the recent session.
| Filing Date | Accepted Date | |
|---|---|---|
| Filing Date | Accepted Date | |
|---|---|---|
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Jun 24, 2026 | 14.42 | 15.26 | 14.41 | 15.02 | 2.21M |
| Jun 23, 2026 | 14.17 | 14.49 | 13.95 | 14.41 | 3.18M |
| Jun 22, 2026 | 15.17 | 15.34 | 14.32 | 14.34 | 2.2M |
| Jun 18, 2026 | 15.68 | 15.86 | 15.08 | 15.30 | 2.51M |
| Jun 17, 2026 | 16.44 | 17.07 | 15.33 | 15.40 | 2.1M |
| Jun 16, 2026 | 16.95 | 17.20 | 16.60 | 16.69 | 1.89M |
| Jun 15, 2026 | 16.92 | 17.01 | 16.30 | 16.76 | 1.64M |
| Jun 12, 2026 | 15.56 | 16.64 | 15.51 | 16.60 | 1.81M |
| Jun 11, 2026 | 15.96 | 16.06 | 15.38 | 15.80 | 3.63M |
| Jun 10, 2026 | 17.50 | 17.69 | 15.93 | 16.23 | 2.87M |
| Jun 09, 2026 | 18.64 | 18.83 | 17.50 | 17.61 | 2.57M |
| Jun 08, 2026 | 19.53 | 20.18 | 18.44 | 18.47 | 2.99M |
| Jun 05, 2026 | 19.53 | 20.62 | 19.31 | 19.34 | 2.3M |
| Jun 04, 2026 | 18.52 | 19.78 | 18.32 | 19.45 | 2.41M |
| Jun 03, 2026 | 18.60 | 18.80 | 17.64 | 18.03 | 2.01M |
| Jun 01, 2026 | 19.47 | 20.04 | 17.72 | 19.12 | 5.61M |
| May 29, 2026 | 16.83 | 18.28 | 16.80 | 17.20 | 3.01M |
| May 28, 2026 | 14.59 | 16.75 | 14.42 | 16.72 | 4.02M |
| May 27, 2026 | 14.69 | 14.99 | 14.11 | 14.82 | 2.76M |
| May 26, 2026 | 15.07 | 15.35 | 14.53 | 14.54 | 2.85M |
Tandem Diabetes Care, Inc., a medical technology firm, specializes in creating, developing, and marketing solutions for individuals globally who manage insulin-dependent diabetes. At the core of its offerings is the t:slim X2 insulin delivery system, an advanced pump platform that integrates the t:slim X2 pump, a disposable 300-unit insulin cartridge, and an infusion set. Tandem further enhances this platform with innovative features like Basal-IQ and Control-IQ technology, as well as G5 Integration capabilities. The company also provides the Tandem Device Updater, enabling users to easily update their pump's software. To facilitate therapy management, Tandem offers t:connect, a web-based application that visually presents diabetes data from the pump, continuous glucose monitoring (CGM) devices, and supported blood glucose meters to patients, their caregivers, and healthcare professionals. Additionally, the Sugarmate mobile application caters specifically to insulin users with diabetes. Tandem has strategic development and commercialization partnerships with leading companies such as Dexcom, Inc. and Abbott Laboratories. Established in 2006 and headquartered in San Diego, California, the company was initially known as Phluid Inc. before rebranding as Tandem Diabetes Care, Inc. in January 2008.
| Employees | 2650 |
| Beta | 1.57 |
| Sales or Revenue | $747.72M |
| 5Y Sales Change% | 2.016% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Medical - Devices |